Purpose or Objective: Whole brain radiotherapy (WBRT) has been the treatment of choice for patients with brain metastases. However, change/decline of neurocognitive functions (NCFs) resulting from impaired hippocampal neurogenesis might occur after WBRT. It is reported that hippocampal sparing would provide the preservation of NCFs. Our study aims to investigate the correlations between hippocampal dosimetry and neurocognitive outcomes in patients receiving hippocampal sparing during WBRT (HS-WBRT).
Results: NCF scores were quite stable before and after HS-WBRT regarding hippocampus-dependent memory. For verbal memory, the corresponding EQD2 values of 0%, 10%, 50%, 80% irradiating the composite hippocampal structure with <12.60Gy, <8.81Gy, <7.45Gy and <5.83Gy respectively were significantly associated with neurocognitive preservation indicated by the immediate recall of Word List Test of Wechsler Memory Scale-III. According to logistic regression analyses, it showed that dosimetric parameters specific to left hippocampus exerted an influence on immediate recall of verbal memory (adjusted odds ratio, 4.08; p-value, 0.042, predicting patients' neurocognitive decline after HS-WBRT). Purpose or Objective: Ongoing clinical trials are evaluating advantage of hippocampal avoiding whole brain radiotherapy (WBRT), however, further basic research focusing on in-vivo description of radiation injury processes is still needed. Using magnetic resonance spectroscopy (MRS), it is possible to measure specific metabolite concentrations in any region of interest in the brain. N-acetylaspartate (NAA) represents a marker of viable neurons. To describe hypothesized post-WBRT neuronal depletion in hippocampus, we prospectively measured changes in NAA concentrations 4 months after WBRT.
Conclusion

Material and Methods:
Patients referred for WBRT with favorable prognosis estimated by graded prognostic assessment and without MRI hippocampal pathology were eligible for study enrollment. Before standard WBRT (twodimensional planning, 2 laterolateral 6 megavoltage fields, dose 10x3.0 Gy delivered by linear accelerator), hippocampal spectroscopy was performed using GE Medical Systems Discovery MR 750 3T. Region of interest was placed through the whole temporal lobi with the voxel layer position adjusted based on the localization of hippocampi. Specialized software was utilized for measurement of absolute NAA concentration in voxels within right, left and both hippocampi. The controle MRS with the same setup parameters was performed 4 months after the end of course of WBRT. Wilcoxon's signed rank test was employed for calculation of NAA concentration changes.
Results: Thirty-five patients (68% mens, mean age 59.5) were enrolled and underwent baseline MRS while only 18 (51%) of them finished the whole protocol with control measurement (15 died before and 2 refused). The most common primary cancer was lung (44%), kidney (20%) and breast (15%). On average, 9 voxels were analyzed per right and left hippocampus. The mean NAA concentration pre-and post-WBRT was 8.47 [mM] and 7.43 [mM] for the right and 8.80
[mM] and 8.04 [mM] for the left hippocampus, respectively. The statistically significant decrease was observed in the right (-11.4%; 95% confidence interval -6.9 to -15.9; p=0.0003) as well as in the left (-8.5%; 95% confidence interval -2.9 to -14.0; p=0.0034) hippocampus.
Conclusion:
Hippocampal MR spectroscopy is feasible and sensitive method for non-invasive measurement of brain radio injury. In our study, we observed correlation between left hippocampal N-acetylaspartate concentration and verbal memory decline with smaller effect of right hippocampus. Robust analysis of pre-irradiation imaging studies may provide valuable predictive biomarkers for decision making for the best radiotherapy approach in the treatment of brain metastases. 
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Material and Methods:
In a cohort of patients treated in curative intent and followed prospectively, those who had completed the treatment one year before were retained for this study. The small bowel loops were delineated during the planning process, but no specific dose constraint was applied. The dosimetric data, converted in 2 Gy equivalent (α/β=3) were confronted to the occurrence of small bowel events: diarrhea, pain, flatulence, bleeding, obstruction, and fistula. Patients were followed every 3 months for the first year then every 6 months, for 3 years, then annually. Late morbidity was defined over the threshold of 90 days from treatment initiation and assessed using the CTC-AE 3.0. Patients who experienced recurrences were censored from the date of their relapse. Dose-effect relationships were assessed using S162 ESTRO 35 2016 _____________________________________________________________________________________________________ mean dose comparisons (T-pair and Kruskal-Wallis tests), log rank tests on event-free survivals, and probit analyses. The highest graded event, or in cases of similar grade the earliest, was considered for analyses. Results: One hundred and fifteen patients were eligible. Of them, 94.8% received concomitant chemoradiotherapy; 12.2% extended-field radiotherapy, and 32.2% nodal sequential boost. Their mean age was 47.5 years. The median follow-up was 35.5 months. A total of 522 events was reported. Focusing on the highest grade per patient: 17 had grade 0, 75, grade 1, 20, grade 2 and 3, grade 3. The prevalence of grade 1 events appeared stable during the study period, ranging between 31.2 and 50%. The one of grade 2 events tended to worsen: 2.2% at 6 months, 4.5% at 1 year, 6.9% at 2 years, and 7.0% at 3 years. Incidences of grade 2-4 events were 0.9% at 6 months, 6.6%, 19.0%, and 27.2% at 1, 2, 3 years respectively. The mean D2cm3 and D0.1cm3 were respectively 68.7±13.6 Gy and 85.8±33.1 Gy and did not differ according to grade (p=0.47 and p=0.52). Comparisons of mean D2cm3 and D0.1cm3 according to grade 0-1 versus 2-4 were not significant (68.0±12.4 vs 71.4±17.7 Gy, p=0.38 and 83.7±26.4 vs 94.5±51.9 Gy, p=0.33 respectively). Log rank tests were performed after splitting patients into 4 groups according to D2cm3 levels: > 80 Gy, 70 to 79 Gy, 60 to 70 Gy and < 60 Gy. No difference was observed for grade 1-4 (p=0.52), grade 2-4 (p=0.52) or grade 3-4 (p=0.21). Probit analyses showed no correlation between both dosimetric parameters and the probability of small bowel events grade 1-4, 2-4, or 3-4 (p ranging from 0.19 to 0.48).
Conclusion: No significant dose-volume effect relationships
were demonstrated between the D2cm3 and D0.1cm3 and the probability of late small bowel morbidity. These two parameters should not limit the optimization process.
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